IBDEI110 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16682,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Cervix Uteri
 ;;^UTILITY(U,$J,358.3,16682,1,4,0)
 ;;=4^Z85.41
 ;;^UTILITY(U,$J,358.3,16682,2)
 ;;=^5063418
 ;;^UTILITY(U,$J,358.3,16683,0)
 ;;=Z85.43^^61^776^89
 ;;^UTILITY(U,$J,358.3,16683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16683,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Ovary
 ;;^UTILITY(U,$J,358.3,16683,1,4,0)
 ;;=4^Z85.43
 ;;^UTILITY(U,$J,358.3,16683,2)
 ;;=^5063420
 ;;^UTILITY(U,$J,358.3,16684,0)
 ;;=Z85.46^^61^776^90
 ;;^UTILITY(U,$J,358.3,16684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16684,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Prostate
 ;;^UTILITY(U,$J,358.3,16684,1,4,0)
 ;;=4^Z85.46
 ;;^UTILITY(U,$J,358.3,16684,2)
 ;;=^5063423
 ;;^UTILITY(U,$J,358.3,16685,0)
 ;;=Z85.47^^61^776^94
 ;;^UTILITY(U,$J,358.3,16685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16685,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Testis
 ;;^UTILITY(U,$J,358.3,16685,1,4,0)
 ;;=4^Z85.47
 ;;^UTILITY(U,$J,358.3,16685,2)
 ;;=^5063424
 ;;^UTILITY(U,$J,358.3,16686,0)
 ;;=Z85.51^^61^776^78
 ;;^UTILITY(U,$J,358.3,16686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16686,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Bladder
 ;;^UTILITY(U,$J,358.3,16686,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,16686,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,16687,0)
 ;;=Z85.528^^61^776^83
 ;;^UTILITY(U,$J,358.3,16687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16687,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Kidney
 ;;^UTILITY(U,$J,358.3,16687,1,4,0)
 ;;=4^Z85.528
 ;;^UTILITY(U,$J,358.3,16687,2)
 ;;=^5063430
 ;;^UTILITY(U,$J,358.3,16688,0)
 ;;=Z85.6^^61^776^74
 ;;^UTILITY(U,$J,358.3,16688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16688,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,16688,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,16688,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,16689,0)
 ;;=Z85.72^^61^776^98
 ;;^UTILITY(U,$J,358.3,16689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16689,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,16689,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,16689,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,16690,0)
 ;;=Z85.79^^61^776^88
 ;;^UTILITY(U,$J,358.3,16690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16690,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,16690,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,16690,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,16691,0)
 ;;=Z85.820^^61^776^77
 ;;^UTILITY(U,$J,358.3,16691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16691,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,16691,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,16691,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,16692,0)
 ;;=Z85.828^^61^776^92
 ;;^UTILITY(U,$J,358.3,16692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16692,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,16692,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,16692,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,16693,0)
 ;;=Z85.71^^61^776^72
 ;;^UTILITY(U,$J,358.3,16693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16693,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,16693,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,16693,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,16694,0)
 ;;=Z65.8^^61^776^144
 ;;^UTILITY(U,$J,358.3,16694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16694,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
